5 citations
,
September 2015 in “Medical hypotheses” Topical sulfonylurea may reduce excessive hair growth caused by certain medications.
September 2024 in “International Journal of Applied Pharmaceutics” A reliable method was developed to measure Finasteride and Tadalafil in rat blood.
December 2025 in “Journal of Human Immunity” JAK inhibitors may help improve symptoms in adults with APECED.
3 citations
,
May 2025 in “Cell Death and Disease” Targeting METTL1 may help slow papillary thyroid cancer growth and spread.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
2 citations
,
November 2004 in “Hospital pharmacy” Certain medications can cause serious side effects, so it's important to report them.
August 2023 in “Expert Review of Clinical Pharmacology” Cetirizine lotion can effectively treat female pattern hair loss.
April 2017 in “Journal of Pharmaceutical Investigation” Indole-based compounds improved ovarian health in rats with PCOS, with L-Tryptophan and Tryptophol being most effective.
January 2015 in “International Journal of Nanomedicine” Anionic squarticles can effectively counteract amitriptyline overdose, improving survival rates.
2 citations
,
October 2022 in “British journal of haematology” A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
October 2025 in “Biomolecules” Intermittent fasting improves metabolism and reduces obesity by affecting specific molecules in fat tissue.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
July 2025 in “Journal of Investigative Dermatology” Enhancing Tregs can protect against alopecia areata.
40 citations
,
September 2014 in “Journal of cosmetic and laser therapy” Transepidermal drug delivery effectively treated areata alopecia with minimal side effects.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
17 citations
,
May 2011 in “Movement Disorders” Finasteride significantly reduced tics and obsessive-compulsive symptoms in patients with Tourette syndrome.
July 2024 in “Journal of Investigative Dermatology”
49 citations
,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
9 citations
,
February 2018 in “Journal of Pharmaceutical and Biomedical Analysis” Quick, selective detection of tadalafil and finasteride in human plasma developed.
7 citations
,
June 2010 in “Journal of The American Academy of Dermatology” Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.
5 citations
,
December 2014 in “Medicine and Pharmacy Reports” Ciproterone acetate improves hair regrowth and acne in most female patients.
April 2026 in “UNC Libraries” Pulsed electric field treatment may help shrink untreated liver tumors.
January 2025 in “Biochemical Pharmacology” Peficitinib can turn human fibroblasts into cells that help grow hair.
January 2025 in “European Journal of Pharmacology” Forsythoside A may help treat hair loss by blocking specific channels.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.